Helen Heslop, MD

Adjunct Professor of Medicine, Institute for Academic Medicine
Full Affiliate Member, Research Institute
Houston Methodist


Biography

Dr. Heslop's initial faculty appointment was as Assistant Member of the Division of Bone Marrow Transplantation in the Department of Hematology-Oncology at the St. Jude Children's Research Hospital, in Memphis in 1991. She was promoted to Associate Member in 1994. She also held an appointment as Associate Professor in the Department of Pediatrics at the University of Tennessee in Memphis. Dr. Heslop received her current appointments at the Baylor College of Medicine in Houston, Texas in 1997. She was named as the first Dan L. Duncan Chair for Baylor College of Medicine in 2006.

Description of Research

Dr. Heslop's research centers on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She currently directs a Lymphoma SPORE program and a program project grant from the NCI, as well as a Specialized Center of Research from the Leukemia and Lymphoma Society. Her research focus is to develop safe and effective T-cell immunotherapies for lymphoma and other Epstein-Barr virus-associated malignancies, including Hodgkin's Disease and nasopharyngeal cancer. Dr. Heslop also runs studies using third party CTLs to treat viral infections after transplant.

Areas Of Expertise

Cancer Adoptive immunotherapy Effector cells Hemopoietic stem cell transplantation
Publications

A backpack revs up T-cell activity
Shum, T & Heslop, HE 2018, Nature Biotechnology, vol. 36, no. 8, pp. 702-703.

Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis
Chinn, IK, Eckstein, OS, Peckham-Gregory, EC, Goldberg, BR, Forbes, LR, Nicholas, SK, Mace, EM, Vogel, TP, Abhyankar, HA, Diaz, MI, Heslop, HE, Krance, RA, Martinez, CA, Nguyen, TC, Bashir, DA, Goldman, JR, Stray-Pedersen, A, Pedroza, LA, Cecilia Poli, M, Aldave-Becerra, JC, McGhee, SA, Al-Herz, W, Chamdin, A, Coban-Akdemir, ZH, Jhangiani, SN, Muzny, DM, Cao, TN, Hong, DN, Gibbs, RA, Lupski, JR, Orange, JS, McClain, KL & Allen, CE 2018, Blood, vol. 132, no. 1, pp. 89-100. DOI: 10.1182/blood-2017-11-814244

The use of chimeric antigen receptor T cells in patients with non-hodgkin lymphoma
Lulla, PD, Hill, LC, Ramos, CA & Heslop, HE 2018, Clinical Advances in Hematology and Oncology, vol. 16, no. 5, pp. 375-386.

Tumor-specific t-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma
Bollard, CM, Tripic, T, Cruz, CR, Dotti, G, Gottschalk, S, Torrano, V, Dakhova, O, Carrum, G, Ramos, CA, Liu, H, Wu, MF, Marcogliese, AN, Barese, C, Zu, Y, Lee, DY, O’Connor, O, Gee, AP, Brenner, MK, Heslop, HE & Rooney, CM 2018, Journal of Clinical Oncology, vol. 36, no. 11, pp. 1128-1139. DOI: 10.1200/JCO.2017.74.3179

Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy
Heslop, HE & Brenner, MK 2018, Molecular Therapy, vol. 26, no. 1, pp. 1-2. DOI: 10.1016/j.ymthe.2017.12.004

Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives—A Single-Center Experience, 2008 to 2016
Yanir, AD, Martinez, CA, Sasa, G, Leung, K, Gottschalk, S, Omer, B, Ahmed, N, Hegde, M, Eunji, J, Liu, H, Heslop, HE, Brenner, MK, Krance, RA & Naik, S 2018, Biology of Blood and Marrow Transplantation. DOI: 10.1016/j.bbmt.2018.03.001

High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
Yanir, AD, Hanson, IC, Shearer, WT, Noroski, LM, Forbes, LR, Seeborg, FO, Nicholas, S, Chinn, I, Orange, JS, Rider, NL, Leung, KS, Naik, S, Carrum, G, Sasa, G, Hegde, M, Omer, BA, Ahmed, N, Allen, CE, Khaled, Y, Wu, MF, Liu, H, Gottschalk, SM, Heslop, HE, Brenner, MK, Krance, RA & Martinez, CA 2018, Biology of Blood and Marrow Transplantation. DOI: 10.1016/j.bbmt.2018.03.029

Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome
Ngwube, A, Hanson, IC, Orange, J, Rider, NL, Seeborg, F, Shearer, W, Noroski, L, Nicholas, S, Forbes, L, Leung, K, Sasa, G, Naik, S, Hegde, M, Omer, B, Ahmed, N, Allen, C, Gottschalk, S, Wu, MF, Liu, H, Brenner, M, Heslop, H, Krance, R & Martinez, C 2018, Biology of Blood and Marrow Transplantation. DOI: 10.1016/j.bbmt.2017.11.019

Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium
NISHIYAMA-FUJITA, YURIKO, KAWANA-TACHIKAWA, AI, ONO, TOSHIAKI, TANAKA, YUKIE, KATO, TAKAFUMI, HESLOP, HELENE, MORIO, TOMOHIRO & TAKAHASHI, SATOSHI 2018, Cytotherapy. DOI: 10.1016/j.jcyt.2018.05.009

Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation
Tzannou, I, Papadopoulou, A, Naik, S, Leung, K, Martinez, CA, Ramos, CA, Carrum, G, Sasa, G, Lulla, P, Watanabe, A, Kuvalekar, M, Gee, AP, Wu, MF, Liu, H, Grilley, BJ, Krance, RA, Gottschalk, S, Brenner, MK, Rooney, CM, Heslop, HE, Leen, AM & Omer, B 2017, Journal of Clinical Oncology, vol. 35, no. 31, pp. 3547-3557. DOI: 10.1200/JCO.2017.73.0655

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Ramos, CA, Ballard, B, Zhang, H, Dakhova, O, Gee, AP, Mei, Z, Bilgi, M, Wu, MF, Liu, H, Grilley, B, Bollard, CM, Chang, BH, Rooney, CM, Brenner, MK, Heslop, HE, Dotti, G & Savoldo, B 2017, Journal of Clinical Investigation, vol. 127, no. 9, pp. 3462-3471. DOI: 10.1172/JCI94306

HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial
Ahmed, N, Brawley, V, Hegde, M, Bielamowicz, K, Kalra, M, Landi, D, Robertson, C, Gray, TL, Diouf, O, Wakefield, A, Ghazi, A, Gerken, C, Yi, Z, Ashoori, A, Wu, MF, Liu, H, Rooney, C, Dotti, G, Gee, A, Su, J, Kew, Y, Baskin, D, Zhang, YJ, New, P, Grilley, B, Stojakovic, M, Hicks, J, Powell, SZ, Brenner, MK, Heslop, HE, Grossman, R, Wels, WS & Gottschalk, S 2017, JAMA Oncology, vol. 3, no. 8, pp. 1094-1101. DOI: 10.1001/jamaoncol.2017.0184

Equal opportunity CAR T cells
Rouce, RH & Heslop, HE 2017, Blood, vol. 129, no. 25, pp. 3275-3277. DOI: 10.1182/blood-2017-04-779983

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Heczey, A, Louis, CU, Savoldo, B, Dakhova, O, Durett, A, Grilley, B, Liu, H, Wu, MF, Mei, Z, Gee, A, Mehta, B, Zhang, H, Mahmood, N, Tashiro, H, Heslop, HE, Dotti, G, Rooney, CM & Brenner, MK 2017, Molecular Therapy. DOI: 10.1016/j.ymthe.2017.05.012

Exhausting alloreactivity of donor-derived CAR T cells
Mamonkin, M & Heslop, HE 2017, Nature Medicine, vol. 23, no. 2, pp. 147-148. DOI: 10.1038/nm.4276

Fall of the mutants: T cells targeting BCR-ABL
Lulla, P & Heslop, HE 2017, Blood, vol. 129, no. 5, pp. 539-540. DOI: 10.1182/blood-2016-12-757336

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Mohammed, S, Sukumaran, S, Bajgain, P, Watanabe, N, Heslop, HE, Rooney, CM, Brenner, MK, Fisher, WE, Leen, AM & Vera, JF 2017, Molecular Therapy, vol. 25, no. 1, pp. 249-258. DOI: 10.1016/j.ymthe.2016.10.016

Fine-tuning the CAR spacer improves T-cell potency
Watanabe, N, Bajgain, P, Sukumaran, S, Ansari, S, Heslop, HE, Rooney, CM, Brenner, MK, Leen, AM & Vera, JF 2016, OncoImmunology, vol. 5, no. 12, e1253656. DOI: 10.1080/2162402X.2016.1253656

Clinical responses with T lymphocytes targeting malignancy-associated ? light chains
Ramos, CA, Savoldo, B, Torrano, V, Ballard, B, Zhang, H, Dakhova, O, Liu, E, Carrum, G, Kamble, RT, Gee, AP, Mei, Z, Wu, MF, Liu, H, Grilley, B, Rooney, CM, Brenner, MK, Heslop, H & Dotti, G 2016, Journal of Clinical Investigation, vol. 126, no. 7, pp. 2588-2596. DOI: 10.1172/JCI86000

T cells for viral infections after allogeneic hematopoietic stem cell transplant
Bollard, CM & Heslop, HE 2016, Blood, vol. 127, no. 26, pp. 3331-3340. DOI: 10.1182/blood-2016-01-628982